auto_awesome_motion View all 4 versions
organization

ECCO

European CanCer Organisation
Country: Belgium
10 Projects, page 1 of 2
  • Open Access mandate for Publications and Research data
    Funder: EC Project Code: 101057361
    Overall Budget: 5,993,220 EURFunder Contribution: 5,993,220 EUR
    Partners: AGE Platform Europe, VUB, University of Coimbra, TRINITY COLLEGE DUBLIN, Ghent University, ECCO, LILT Milano Monza Brianza, UBC, EAPC, Jagiellonian University...

    Background: Most people who have cancer are older people, affecting millions of Europeans each year. Providing high-quality, equitable, and cost-effective care across the continuum of supportive, palliative, end-of-life, and survivorship care for both patients and their frequently overburdened family caregivers is highly relevant from an economic, a healthcare and a prevention perspective. Aims: The EU NAVIGATE project is an interdisciplinary, cross-country and intersectoral project aiming to evaluate the effectiveness and cost-effectiveness of a Navigation Intervention (NavCare-EU) for older people with cancer and their family caregivers in different health care systems in Europe. Concept and methods: NavCare-EU is a person- and family-centered non-pharmacological intervention in which navigators collaborate with patients and families to improve quality of life and well-being, foster empowerment, and facilitate timely and equitable access to health and social care services and resources as needed, throughout the supportive and palliative care continuum. NavCare-EU is based on the existing and successfully tested Nav-Care intervention from Canada. Effectiveness and cost-effectiveness will be evaluated through an international pragmatic randomized controlled trial among 532 cancer patients aged 70 years and older and their family caregivers. Robust mixed-method subgroup analyses and in-depth process and implementation evaluations are also included. Impact: EU NAVIGATE will advance the state of the art by providing innovative solutions to the complex supportive and palliative care needs experienced by older cancer patients and their families, which is implementable in the real world and in diverse health care systems and contexts. User and stakeholder involvement methods are integrated throughout the whole project.

  • Open Access mandate for Publications and Research data
    Funder: EC Project Code: 101057482
    Overall Budget: 7,292,900 EURFunder Contribution: 7,235,020 EUR
    Partners: FFUND BV, INT, UM, FUNDATIA YOUTH CANCER EUROPE, CLB, STICHTING INTEGRAAL KANKERCENTRUM NEDERLAND, ECCO, Maria Sklodowska-Curie National Research Institute of Oncology, Institut Gustave Roussy, EORTC...

    STRONG-AYA is a new, interdisciplinary, multi-stakeholder European network to improve healthcare services, research and outcomes for Adolescents and Young Adults (AYA) with cancer, defined as individuals aged 15-39 years at cancer diagnosis. AYAs with cancer form a unique group; they face age-specific issues (e.g. infertility, unemployment, financial problems) and decreased quality of life due to cancer and its treatment. Unlike dedicated healthcare and trials for pediatric cancer patients, AYA-specific healthcare services are scarce and vary across Europe. AYAs who are at the core of society and economy need access to age-adjusted and high-quality healthcare. AYA-care and research will benefit from collection and pooling of patient-centered data and collaboration among all stakeholders: patients, healthcare professionals, scientists, and policymakers. Our consortium of clinical and scientific leaders in AYA-care, data science and registries, European Cancer Organisation, Youth Cancer Europe and EORTC will build on previous initiatives and EU grants. Within STRONG-AYA we will set up a value-based healthcare research ecosystem to develop data-driven, interactive policy and visualization tools that bring, in co-creation with all stakeholders including patients, novel insights into AYA healthcare. The project objectives, include: 1) Development of a Core Outcome Set (COS) for AYAs with cancer; 2) Implementation of the COS in 5 national healthcare systems (FR, IT, NL, UK, PL) and establish national infrastructures for outcome data management and clinical decision-making and a pan-European ecosystem that also welcomes future European countries; 3) Disseminate outcomes and facilitate interactions between national and pan-European stakeholders to develop data-driven analysis tools to process and present relevant outcomes, establish feedback loops for AYA cancer patients and the healthcare systems, and improve the reporting and assessment of outputs towards policy-makers.

  • Open Access mandate for Publications and Research data
    Funder: EC Project Code: 101097026
    Overall Budget: 8,478,000 EURFunder Contribution: 8,478,000 EUR
    Partners: VULSK, Palacký University, Olomouc, TAU, TASMC, FZMB GMBH, UoA, PREDICTBY RESEARCH AND CONSULTING S.L., UAB ORIENTOS, JAXBIO TECHNOLOGIES LTD, ECCO...

    Project SANGUINE addresses the objectives raised by the Cancer Mission Call, which emerged from the growing societal challenge faced by European citizens. According to the European Cancer Information System (ECIS), each year, 2.7 million people in the EU are diagnosed with cancer. The SANGUINE project focuses on hematological malignancies, which account for 10% of those cases, and aims to target the four objectives of the Cancer Mission: (1) understanding, (2) prevention, including screening and early detection, (3) diagnosis, and (4) quality of life improvement of the patients and their relatives. The project introduces a novel minimally-invasive blood test that detects and classifies a set of hematological malignancies. The test is based on detecting a combination of epigenetic biomarkers in DNA from peripheral blood cells and in cell-free DNA. The SANGUINE test will provide superior sensitivity at low-cost which is ideal for screening purposes. This is enabled by direct fluorescent labeling of epigenetic marks in patient DNA and its analysis on a custom designed microarray – the HemaChip. SANGUINE team consists of a comprehensive and strong team of expert that will address medical, technological and social aspects of the developed diagnostic test. Expertise from the medical field includes clinical research, technology development and access to patients. This will enable optimization of the test for hematological malignancies following a user-centric approach and experiencing its implementation in “real-life” clinical settings. The social part of the team includes researchers and patient organization that will promote accessibility of the test to patients and individuals at-risk for screening, early detection and disease management, in combination with a study aiming to increase the screening rates. Ultimately, our project will provide validated reagents, HemaChips and data analysis software ready for large scale screening and early stage commercialization.

  • Funder: EC Project Code: 257743
    Partners: URV, LABMAN, FHG, KTH, IMEC, Oslo University Hospital, ICSENSE, ECCO, MRC, THINXXS...
  • Open Access mandate for Publications and Research data
    Funder: EC Project Code: 101057332
    Overall Budget: 9,033,750 EURFunder Contribution: 9,033,750 EUR
    Partners: Design School Kolding, Institute of Oncology Ljubljana, Charité - University Medicine Berlin, UMIT TIROL, ERASMUS MC, ECCO, TUM, Leiden University Medical Center, RSD, RS...

    Patients with cancer often have to make complex decisions about treatment, with the options varying in risk profiles and effects on survival and quality of life. Data-driven decision-support tools (DSTs) have the potential to empower patients, support personalized care, improve health outcomes, and promote health equity (optimal decisions also for underserved groups). However, DSTs currently seldom consider quality of life or individual preferences, and their use in clinical practice remains limited. To address these challenges, the 4D PICTURE consortium will further develop a promising methodology, MetroMapping, to redesign care paths that include novel DSTs. We will better predict treatment outcomes by developing innovative algorithms and incorporating patient experiences, values and preferences, using AI-based models. In co-creation with patients and other stakeholders, we will develop data-driven DSTs for patients with breast cancer, prostate cancer and melanoma. We will evaluate these DSTs as part of MetroMapping as well as stand-alone, to ensure their sustainability as well as addressing social and ethical issues. We will explore the generalizability of MetroMapping and the DSTs to other types of cancer and across other EU member states. Improved care paths integrating comprehensive DSTs will empower patients, their significant others and health care providers in decision making, and strengthen care at the system level by improving resilience and efficiency. Whereas the 4D PICTURE consortium includes leaders in modelling, AI, decision making, citizen science, service design, ethics, risk communication, and policy making, this project will impact clinical practice and science across Europe and beyond.